Market revenue in 2023 | USD 3,111.3 million |
Market revenue in 2030 | USD 4,181.6 million |
Growth rate | 4.3% (CAGR from 2023 to 2030) |
Largest segment | Cannabis/marijuana |
Fastest growing segment | Cannabis/Marijuana |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD, Other Drug Types |
Key market players worldwide | Quest Diagnostics Inc, Abbott Laboratories, Clinical Reference Laboratory, Cordant Health Solutions, ZeOmega, Psychemedics Corp, Millennium HealthCare Inc, Mayo Clinic, Precision Diagnostics, LGC Group, Labcorp Drug Development, Legacy Medical, Drugscan, USDTL |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug of abuse testing services market will help companies and investors design strategic landscapes.
Cannabis/marijuana was the largest segment with a revenue share of 24.24% in 2023. Horizon Databook has segmented the U.S. drug of abuse testing services market based on alcohol, cannabis/marijuana, cocaine, opioids, amphetamine & methamphetamine, lsd, other drug types covering the revenue growth of each sub-segment from 2018 to 2030.
In the same year, around 20.3 million people aged 12 or above were suffering from Substance Use Disorder (SUD), including 8.1 million people suffering from illicit drug use disorder and 14.8 million people suffering from alcohol use disorder.
In addition, local presence of major drugs of abuse testing service providers and continuous strategic initiatives undertaken by them are anticipated to support the market. For instance, in May 2018, the U.S.-based Omega Laboratories introduced its new Omega Hair 17-panel drug test. This offering provided tests for around 45 different substances.
Furthermore, workplace drug testing is allowed in the U.S. The Drug-Free Workplace Act of 1988 demands all federal grantees and federal contractors to admit that they will provide drug-free workplaces for obtaining a grant or contract from a federal agency. This has created lucrative opportunities for workplace drug testing in the U.S.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. drug of abuse testing services market , including forecasts for subscribers. This country databook contains high-level insights into U.S. drug of abuse testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account